Rick Simpson Oil (RSO) in Oklahoma: The Complete Guide by OilWell Cannabis

If you’re reading this from Oklahoma City, Tulsa, Norman, Lawton, or anywhere across the Sooner State’s vast prairie landscape, you already know something most of the country doesn’t: Oklahomans don’t wait around for solutions. When the medical system falls short, when chronic pain becomes a daily battle, when PTSD from military service or life’s traumas won’t quiet down at night, Oklahomans roll up their sleeves and look for answers. That’s exactly why Rick Simpson Oil matters here — and why we at OilWell Cannabis, based in Houston but serving Oklahoma with nationwide shipping, believe you deserve the most honest, comprehensive education about RSO available anywhere.

Oklahoma has one of the highest per-capita rates of medical marijuana patients in the nation since State Question 788 passed in 2018. Yet we know from speaking with Oklahomans across the state — from rural Cimarron County to urban Oklahoma County — that having legal access doesn’t solve everything. Medical cards are expensive. Dispensary quality varies wildly, with some shops selling products that don’t match their labels. Rural patients drive hours to reach the nearest dispensary, only to find limited options. Veterans in Lawton and Enid tell us they’re tired of being prescribed pills that don’t work. Cancer patients at OU Health and Cancer Treatment Centers of America in Tulsa search for supportive options that integrate with their oncologists’ protocols rather than replacing them. People managing chronic pain in the Panhandle, anxiety in the suburbs, or insomnia in small towns across Oklahoma are looking for something better.

This guide exists for you. We don’t sell snake oil, and we don’t sell hope. We sell rigorously formulated, lab-tested, multi-cannabinoid RSO products that honor Rick Simpson’s original vision while fixing the problems that made his traditional oil unpredictable, unsafe, and legally risky. More importantly, we give you every single detail — our complete formulas, our sourcing, the science behind each compound, and the real-world context from seven ABC13 features that established us as Houston’s go-to cannabis authority.

Who is Rick Simpson, and Why Does His Story Matter in Oklahoma?

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical professional — he was a blue-collar power engineer and maintenance worker, much like many Oklahomans who work in our state’s energy sector, manufacturing plants, and industrial facilities. His path into cannabis began not with research but with personal suffering after a workplace injury in 1997. While working at a hospital in Moncton, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. The medications doctors prescribed either failed to help or made his condition worse. When he discovered cannabis provided relief but his physician refused to consider it, he began exploring cannabis oil himself .

Simpson’s interest deepened after learning about a 1974 study funded by the National Institute of Health at the Medical College of Virginia, where THC was reported to slow tumor growth in mice. That study — originally intended to demonstrate harm — became foundational to his advocacy, even though its findings were never replicated in controlled human cancer trials .

The pivotal moment came in 2003. Simpson reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, he applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification, biopsy confirmation, or clinical follow-up was ever published in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil .

Important context for Oklahomans: Simpson’s account is personal testimony, not medical evidence. The absence of clinical documentation means these events cannot be evaluated as scientific proof. However, they are historically significant as the catalyst for a global movement. In Oklahoma, where personal stories of healing often spread through tight-knit communities, we understand why anecdotal accounts resonate. But we also believe you deserve the full truth: what worked for one man in Nova Scotia two decades ago is not the same as a clinically validated treatment protocol.

The Traditional RSO Protocol: What Simpson Recommended

Simpson’s core recommendation was a structured oral protocol delivering 60 grams of concentrated cannabis oil over approximately 90 days. He described this as a cancer treatment protocol, though he also recommended it for diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, and other conditions .

The 60-Gram Titration Schedule

• Week 1: Start with a dose the size of half a grain of rice — roughly 10-15 mg of oil — taken three times daily. Total daily intake: 30-45 mg.
• Weeks 2-5: Double the dose every four days to build THC tolerance gradually. Target: approximately 1 gram (1,000 mg) of oil per day by week five, divided into three doses.
• Weeks 5-12: Maintain 1 gram per day until all 60 grams are consumed.

Administration Methods

• Oral (primary): Place dose under tongue or swallow for systemic absorption.
• Topical (secondary): Apply directly to skin lesions for external cancers.
• Inhalation (not recommended as primary): Simpson acknowledged vaping for immediate symptom relief but insisted oral dosing was essential for sustained therapeutic exposure.

Critical Problems with This Protocol for Oklahoma Patients

This protocol was designed around crude, unstandardized material and carries significant risks that Oklahomans need to understand:

• No controlled trial validation: No published randomized controlled trials, cohort studies, or documented case series evaluate this specific protocol for any condition.
• Assumes crude, unstandardized material: The 60-gram quantity assumes single-strain, THC-dominant extract with no standardized potency. Actual THC content varied wildly.
• Very high THC exposure: At peak dosing, patients consumed roughly 600-900 mg of delta-9 THC daily. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5-20 mg per day.
• Real risks at these doses: Consuming 600-900 mg of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [1][13][14][15].
• Oncology context: Patients with active cancer are medically complex. Using unregulated, unstandardized cannabis oil as a primary treatment — potentially in place of proven therapies — introduces harm beyond the oil itself.

For Oklahomans considering cancer treatment: If you’re receiving care at OU Health Stephenson Cancer Center, Cancer Treatment Centers of America in Tulsa, or any of Oklahoma’s regional oncology programs, please discuss any cannabinoid use with your oncology team. RSO can be a supportive tool, not a proven cure. Delaying or foregoing evidence-based treatment for unproven alternatives can have irreversible consequences.

Traditional RSO vs. Modern Formulated RSO: What Oklahomans Need to Know

The term “RSO” is now used loosely across the cannabis industry. Many products labeled RSO bear little resemblance to what Simpson originally made. In Oklahoma dispensaries, you might see “RSO” that varies dramatically from one batch to another. Here’s the honest comparison:

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol (toxic solvents)	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant (60-90%), uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets (553 mg/mL)
Lab testing	Not performed	Full panel testing for potency, terpenes, pesticides, heavy metals, residual solvents, microbial contaminants
Residual solvents	Significant risk with naphtha	Controlled and tested to FDA Class 3 limits
Product formats	Single thick oil only	Sublingual oil AND vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as separate ingredient at 1,500 mg
Delta-9 THC exposure	600-900 mg/day at peak dosing	90 mg total in entire 30 mL bottle (3 mg/mL)
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why Our Formulas Diverge from Traditional RSO: The Science Behind Our Choices

Our formulations aren’t traditional RSO. They’re informed by the tradition but depart from it in deliberate, evidence-motivated ways that matter specifically for Oklahomans:

1. Multi-Cannabinoid Approach for Broader Therapeutic Potential

Traditional RSO relied on whatever single strain the maker grew. Our formulas intentionally include seven cannabinoids — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — because the entourage-effect literature suggests potential benefit from cannabinoid diversity [20][29]. For Oklahoma veterans dealing with PTSD plus chronic pain, or cancer patients managing nausea plus anxiety, a single-cannabinoid approach often falls short. Each cannabinoid engages different receptor systems and pathways.

2. Terpene Preservation and Addition

Traditional RSO had essentially no terpene content due to solvent and heat destruction. We include live terpenes at 5% with a specific seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. These aren’t just for flavor — each terpene has its own bioactivity profile that complements the cannabinoids [20]-[28]. For Oklahomans who’ve become terpene-savvy through the state’s medical program, this matters.

3. THCa as a Separate Ingredient for Patient Control

Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity via COX-2 inhibition and PPARγ agonism that is lost when THCa converts to THC [12].

This is the game-changer for Oklahoma: You control whether your RSO stays non-psychoactive for daytime use or becomes fully activated for nighttime potency. No other product gives you this choice.

4. Reduced Delta-9 THC Dominance

Traditional RSO was overwhelmingly delta-9 THC — often 60-90% of total content. Our formula uses delta-9 THC at only 90 mg while distributing the remaining cannabinoid content across delta-8 THC (6,000 mg), CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects modern cannabinoid research rather than single-compound dominance.

5. Product Format Innovation for Different Needs

Simpson envisioned only one format: oral oil from a syringe. We offer both a 30 mL sublingual oil and a 1-gram vape cartridge, each with format-specific formulations acknowledging that different delivery routes have different pharmacokinetic profiles [14]. For Oklahomans needing immediate relief from breakthrough pain or panic attacks, our vape cartridge delivers effects in 1-2 minutes. For sustained daily management, our sublingual oil provides 4-6 hour duration.

The OilWell Cannabis Story: From a Dog Named Bentley to Serving Oklahoma

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. But our story begins where many Oklahoma stories do — in hardship, determination, and the refusal to give up on family.

Colin grew up in McAllen, Texas, right across the river from Reynosa, Mexico. The Borderplex region is one of the most economically challenged and dangerous areas along the US-Mexico border — a place of stark contrasts where opportunity and violence coexist. By sixteen, Colin had left home, navigating a world where best friends were killed or imprisoned. He learned early that when the system fails you, you find another way.

He chose cannabis over darker paths, seeing it as a safer and more beneficial alternative. Years later, he became a formally trained software engineer, doing custom development work for Baylor College of Medicine in the Texas Medical Center — one of the nation’s most prestigious medical institutions. That combination of deep cannabis plant knowledge and medical-grade technical precision defines everything we do.

Bentley: The Dog Who Started It All

Our company’s origin story begins with a dog named Bentley. Bentley was more than a pet — he was family who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants: euthanasia was the only humane option. Bentley was paralyzed in his back legs. Pain medications would destroy his organs. The choice was painful decline or immediate mercy killing.

But giving up wasn’t an option. In a desperate search, Colin stumbled upon CBD through a question that changed everything: “You’ve moved how many tons of weed and you’ve never heard of CBD?” asked a rescue worker named Jessica.

Colin had cannabis experience — but it was recreational. He’d never explored therapeutic applications. Jessica’s question exposed a blind spot that became a mission.

Determined to save Bentley, Colin created CBD golden paste — a specialized cannabinoid formula for pets. It wasn’t a cure, but it delivered what veterinary medicine said was impossible: Bentley got up, walked over, and brought his ball to play. From paralyzed and facing euthanasia to fetching his ball. This wasn’t placebo — dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, dying naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced:

• Neurodegeneration led to understanding CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection
• Dementia led to CBC’s role in neurogenesis
• Glaucoma led to THC’s CB1 agonism for intraocular pressure reduction
• Crippling arthritis led to multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. This is why our RSO contains seven cannabinoids — not as a marketing gimmick, but because a decade of real-world formulation testing on a patient Colin loved more than anything proved it necessary.

Colin’s Personal Battle: PTSD and Benzo Addiction

Colin also knows pharmaceutical dependence personally. He struggled with severe PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — a notoriously difficult and dangerous feat — using the cannabinoid knowledge he developed keeping Bentley alive.

Our Peace Gummies formula was created during midnight experiments while fighting through benzo withdrawal. Colin personally uses the vape form to manage his insomnia and severe PTSD. This is not theoretical knowledge. He lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills don’t.

Doctors Use Our Formulas

Over time, the therapeutic benefits Colin discovered through Bentley became the core of our work. We’ve developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. Our focus has always been making cannabis accessible and effective for everyone — including vegans, diabetics, and those with specific health needs.

ABC13: Houston’s #1 News Source Recognized Our Authority

Between 2019 and 2023, ABC13 Houston featured Colin and OilWell in seven comprehensive news segments. Why should Oklahomans care about Houston media coverage? Because it demonstrates the level of expertise and credibility we bring to Oklahoma. When America’s fourth-largest city needed to explain cannabis law, Delta-8 science, or community health leadership, they called us — not once, but seven times.

Our foundational quote from September 2019 captures our philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Our Operations: Real, Licensed, Verified

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). We’ve been operating since 2019, generate approximately $1 million in annual revenue, maintain a near-5.0 Google rating, and are Texas DSHS licensed. All artwork, formulations, and packaging are created in-house in Houston using only our own recipes and ideas.

For Oklahomans, this means: You’re not buying from a faceless online brand or a dispensary that sources mystery products. You’re getting professionally manufactured, lab-tested formulations from a company with verified media credibility, a licensed operation, and a public track record of ethical decision-making.

Our Four Core Principles: Why Oklahoma Matters to Us

1. Accessibility Over Gatekeeping

No medical card required. Anyone age 21+ can purchase. We ship nationwide, including to every corner of Oklahoma — from Guymon to Idabel, from Miami to Durant. Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally.

For Oklahomans who can’t afford the medical card fees ($100+), who live hours from the nearest dispensary, or who’ve been denied cards due to qualifying condition restrictions, our Farm Bill-compliant products offer legal access without barriers.

2. Patient-Controlled Potency

THCa is sold in its acidic, non-psychoactive form. YOU decide whether to use it raw for daytime relief or decarboxylate it into delta-9 THC for full nighttime potency.

This matters for Oklahoma’s working families: If you’re farming in Garfield County, working oil fields in Woodward, or serving in law enforcement in Oklahoma City, you can’t be impaired during the day. Use our RSO raw — zero psychoactivity, full anti-inflammatory benefit. When you get home and need serious relief, decarboxylate and activate the full 1,405 mg of THC potential.

3. Open-Source Formulas

We publish our complete formulas publicly — every cannabinoid, every milligram amount, every percentage. If you can’t afford $129.99 for our sublingual oil, you can source the ingredients and make your own version.

For Oklahomans on fixed incomes: This isn’t marketing — it’s our promise. Simpson gave his oil away free and taught people to make it. We adapted that ethos for the modern marketplace: sell a professionally manufactured product and publish the recipe for those who need to DIY.

4. Evidence-Informed, Not Evidence-Overstating

The GENERAL KNOWLEDGE section that follows represents our commitment to honest education about what science actually says. We apply the same evidence standards to our own products that we apply to the entire cannabinoid field. Where Simpson relied on personal testimony, we rely on published literature and institutional sources [1]-[29].

Farm Bill Compliance and Oklahoma Legal Framework

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This is the foundation of our product design.

Our RSO Sublingual Oil contains only 90 mg of delta-9 THC in the entire 30 mL bottle — 3 mg per mL — well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under federal law.

THCa: The Legal Game-Changer for Oklahoma

THCa is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC, making it Farm Bill compliant at point of sale. This distinction is legally significant and creates a paradigm shift in cannabis accessibility.

You can legally purchase, possess, and transport our RSO in Oklahoma. Then, at your discretion in the privacy of your home, you can decarboxylate the THCa into delta-9 THC by heating the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500 mg of THCa into approximately 1,315 mg of delta-9 THC. Combined with the existing 90 mg, you get ~1,405 mg total delta-9 THC — psychoactive potency comparable to traditional illegal RSO, achieved 100% legally because the conversion happens after purchase.

Conversion chemistry: 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation (accounting for CO₂ loss).

For Oklahomans: This means you can order our product online, have it shipped discreetly to your home in Oklahoma City, Tulsa, or any rural route, and activate it legally. No medical card. No dispensary visit. No legal risk at purchase.

Important legal notice: Customers are responsible for understanding and complying with Oklahoma state laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility. Our products are void where prohibited by law.

Open-Source Formulas: Why We Publish Everything

We publish our complete RSO formulas publicly. If you can’t afford our products, you can see exactly what they contain and make your own version.

Our RSO Sublingual Oil Formula (published openly):

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

• Live Terpenes: 5%
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg

Our RSO Vape Cartridge Formula (published openly):

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%
• Format: 1 Gram cartridge

Terpene Profile (both products):

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene – pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

For Oklahomans who want to DIY: If you can source cannabinoid distillates and isolates, you can replicate these formulas exactly. We provide this because Simpson gave his oil away free and taught people how to make it. We honor that ethos for the modern marketplace.

Bentley’s Original CBD Golden Paste Recipe

Before we open-sourced our RSO formulas, we published the CBD golden paste recipe that saved Bentley’s life:

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on pet size; consult veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes)
2. Add coconut oil and pepper, mix thoroughly
3. Cool and store in refrigerator (up to 2 weeks)
4. Add CBD oil before serving

Serving: Mix small amount with pet’s food 1-2 times daily. Monitor and consult veterinarian.

This recipe — published years before our RSO formulas — demonstrates that open-source is our foundational behavior, not a marketing strategy.

The Decarboxylation Choice: Patient-Controlled Potency

Traditional RSO was always fully psychoactive. Our product gives you three distinct usage options:

Option 1 — Raw, no heat: All 1,500 mg stays as THCa — completely non-psychoactive. Use this for daytime anti-inflammatory benefits without impairment. Perfect for Oklahomans who work in safety-sensitive jobs, drive for a living, or need functional relief.

Option 2 — Fully activated, home decarboxylation: Heat at 260°F for 45-60 minutes to convert THCa to delta-9 THC. This yields ~1,405 mg total delta-9 THC. Use this for serious nighttime relief, cancer support protocols, or when psychoactive effects are therapeutically beneficial.

Option 3 — Partial activation: Transfer a portion of oil to a separate oven-safe container and decarboxylate only what you need, preserving the rest in raw form. This gives you precise control over your daily cannabinoid exposure.

Option 4 — Vape, auto-decarboxylation: Our vape cartridge vaporizes at 400-450°F, instantly converting THCa with each puff. This is the fastest RSO delivery method available.

Solvent-Free Production: The Safety Standard Oklahoma Deserves

Traditional RSO used naphtha or isopropyl alcohol — neither food-grade. Naphtha is a petroleum hydrocarbon mixture that may contain benzene, toluene, and other carcinogens. Incomplete solvent purging leaves harmful residues in the finished oil.

Our approach: No solvents. We blend individual cannabinoid distillates and isolates in a controlled production environment. No naphtha, no isopropyl alcohol, no butane, no extraction solvents in the finished product.

Carrier: Organic MCT oil — a food-grade lipid that facilitates sublingual absorption and provides neutral taste. No tar-like consistency. No solvent-residual odor.

Testing: Third-party lab panels cover:

• Cannabinoid potency (HPLC/UHPLC, ±2% accuracy)
• Terpene profile
• Pesticides (400+ compound screening via LC-MS/MS and GC-MS/MS)
• Heavy metals (ICP-MS for arsenic, cadmium, lead, mercury below FDA limits)
• Residual solvents (headspace GC, FDA Class 3 limits <5,000 ppm)
• Microbial contaminants (E. coli, Salmonella, Aspergillus, comprehensive pathogen screening)

Certificates of Analysis: Available on request and through our website. Every Oklahoman deserves to know exactly what’s in their medicine.

Our Broader Product Portfolio

Beyond RSO, we produce a range of cannabinoid products developed from Colin’s decade of formulation experience:

Asshole Peach — Our most popular product. Carefully formulated for euphoric, long-lasting sensation. Particularly favored by Oklahoma veterans for PTSD and pain relief without aggressive psychoactivity.

Peace Gummies — Developed from Colin’s personal benzo withdrawal experience. Available in gummy and vape forms for quick relief. Many Oklahomans use this for sleep and anxiety management.

Custom Creations — We design tailored products for specific cannabinoid ratios, delivery formats, or health circumstances. This includes formulations for vegans, diabetics, and those with specific dietary needs. If you’re an Oklahoman with unique health requirements, we can create something just for you.

Two Product Formats for Different Oklahoma Needs

RSO Sublingual Oil — $129.99

Specs:

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%
• Organic MCT oil base
• Graduated dropper for precise 0.1 mL dosing

Pharmacokinetics:

• Onset: 15-45 minutes (sublingual absorption)
• Peak: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (partially bypasses first-pass liver metabolism)
• Approximately 40-60 doses per bottle

RSO Vape Cartridge — $49.99

Specs:

• 1-gram cartridge
• 900+ mg total cannabinoids
• Six cannabinoid ratio (no separate delta-9 THC — THCa auto-decarbs at vaping temp)
• Live terpenes at 5%+
• 510-thread universal battery compatibility

Pharmacokinetics:

• Onset: 1-2 minutes (fastest delivery)
• Peak: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable with inhalation technique)
• Automatic THCa decarboxylation at 400-450°F

When to Use Each Format in Oklahoma

Use Case	Recommended Format	Why It Works for Oklahomans
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset — critical for breakthrough moments
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration for all-day management
Maximum bioavailability	Sublingual	13-19% absorption efficiency
Portability/discretion	Vape	Compact for travel across Oklahoma’s vast distances
Precise dosing	Sublingual	Dropper allows exact mg control
Daytime non-psychoactive	Sublingual (raw)	THCa stays inactive — zero impairment for work/driving
Nighttime psychoactive	Sublingual (decarbed) or Vape	Full activation for serious symptom relief

Competitive Comparison: Why OilWell RSO Stands Out in Oklahoma

vs. Oklahoma Medical Marijuana Dispensary RSO

Dimension	Oklahoma Dispensary RSO	OilWell RSO
Cannabinoid profile	Typically THC-only, single-strain	7 defined cannabinoids at specific ratios
CBG content	Usually 0 mg	3,000 mg
CBN content	Usually 0 mg	750 mg
CBC content	Usually 0 mg	750 mg
Patient-controlled potency	No — always fully psychoactive	Yes — THCa non-psychoactive until you activate it
Access requirements	Oklahoma medical card	Age 21+ only, no card required
Delivery	Must drive to dispensary	Ships directly to your Oklahoma address
Lab testing	Varies significantly	Full panel with COAs provided
Price transparency	Often unclear	Published formula, open-source option

vs. National CBD Brands (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg (16x more)
CBD content	~950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg (193x more)
CBN content	0.7 mg	750 mg (1,071x more)
Delta-8 THC	0 mg	6,000 mg
THCa (convertible)	Minimal	1,500 mg (~1,315 mg delta-9 THC potential)
Psychoactive option	No meaningful effect	Yes — via THCa decarboxylation
Approximate price	$40-50	$129.99 (better value per mg)

Condition-Specific Usage Context for Oklahomans

IMPORTANT DISCLAIMER: These usage contexts are informed by cannabinoid research cited in our GENERAL KNOWLEDGE section and our formulation rationale. They are NOT medical prescriptions, NOT FDA-approved treatment protocols, and NOT a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids. Individual results may vary.

Chemotherapy-Related Nausea and Appetite Support

For Oklahomans at OU Health, Cancer Treatment Centers of America, or regional oncology centers:

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)

Evidence context: Delta-8 THC antiemetic evidence [9], delta-9 THC nausea/vomiting evidence [1][13], CBD anxiolytic buffering [3]

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy, Back Pain)

For Oklahomans dealing with pain from physical labor, injuries, or conditions:

• Daytime: 0.3-0.5 mL raw sublingual — anti-inflammatory cannabinoid exposure without impairment
• Nighttime: 0.5-1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep Support

For Oklahomans struggling with insomnia:

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL: Delivers 50 mg CBN — the dosage investigated in 2024 sleep literature
• At 1.0 mL: Delivers 25 mg CBN — above the 20 mg threshold associated with reduced sleep disturbance

Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature

Anxiety and Stress

For Oklahomans managing anxiety, PTSD (especially veterans), or chronic stress:

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety pathways without impairment
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture

Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

General Titration Principle for Oklahomans

Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications (especially important for Oklahomans on multiple prescriptions), and other factors.

If you’re currently receiving care at the Oklahoma City VA Medical Center, Stillwater Medical Center, or any healthcare facility, discuss cannabinoid use with your provider to avoid drug interactions.

Delivery and Accessibility to Oklahoma

Houston Same-Day Delivery Zones (Reference for Oklahoma Context)

While our same-day delivery is Houston-only, understanding our logistics shows our commitment to accessibility:

• Texas Medical Center (TMC): FREE 2-4 hour delivery to MD Anderson, Memorial Hermann, Methodist, Texas Children’s, St. Luke’s (10+ million patient visits annually)
• Inner Loop (610): $5 delivery to Montrose, River Oaks, Galleria
• Beltway 8: $10 delivery to Memorial, Spring Branch, Hobby Airport area
• Greater Houston suburbs: $15 delivery to Katy, Sugar Land, The Woodlands
• Extended region (60 miles): $20-25 same-day if ordered before 2 PM

Why this matters for Oklahomans: We built the most sophisticated delivery infrastructure in our home market. We apply that same logistics expertise to serving Oklahoma.

Shipping to Oklahoma: Fast, Discreet, Reliable

All 50 states where Farm Bill-compliant products are legal:

• USPS Priority Mail: 2-3 business days to any Oklahoma address
• FedEx/UPS Ground: 3-5 business days
• Discreet packaging: No cannabis branding visible on exterior
• Tracking: Provided for all orders
• Temperature-stable packaging: Essential for Oklahoma summers (we know it gets hot in August)
• Signature-required option: Available for added security

International shipping: We ship internationally to jurisdictions where hemp-derived products with <0.3% delta-9 THC are permitted. All packages include full documentation, Certificates of Analysis, and receipts for customs. Customer accepts all customs and legal responsibility.

PANDEM1C SEO Technology: Making OilWell Discoverable

Our proprietary PANDEM1C SEO system uses 14 million distinct geopolitical locations and 300+ AI models to drive organic search visibility across six continents. What this means for Oklahomans: When you search “RSO Oklahoma,” “buy RSO Tulsa,” “legal cannabis oil Oklahoma City,” or “cannabinoids for pain Oklahoma,” our educational content is designed to be findable and helpful.

Contact us:

• Phone: (832) 416-2816
• Email: [email protected]
• Website: https://oilwellcbd.com/
• Instagram: @oilwellcbd

How Our Formulas Connect to the Evidence

Every cannabinoid in our RSO — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — has its own evidence profile in the peer-reviewed literature [1]-[29]. Every terpene — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — is covered with preclinical and review-level evidence.

We anchor our product claims to per-compound evidence summaries that explain:

• What is well-supported by human clinical data
• What is emerging from review and preclinical literature
• What is overstated relative to current evidence

We do not exempt ourselves from the same evidence standards we apply to the entire cannabinoid field. That is intentional. You deserve the best possible version of information so you can give it a fair shot and decide for yourself whether it’s right or wrong for you.

GENERAL KNOWLEDGE: The Science Behind Every Compound

Research Method and Evidence Weighting

We prioritize sources in this order: human clinical evidence → systematic reviews/meta-analyses → NIH/institutional summaries → mechanistic/preclinical literature. This weighting matters because the evidence base is not evenly distributed. CBD and delta-9 THC have the strongest human data; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes depend more on reviews, animal work, and early translational studies [1]-[29].

Institutional Baseline from NIH and Related Sources

• NCCIH states the strongest established cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea/vomiting, and HIV/AIDS appetite/weight loss. Modest evidence exists for chronic pain and MS symptoms; many other uses remain early-stage [1].
• FDA has not approved the cannabis plant itself for medical use, though purified CBD (Epidiolex) and synthetic THC analogues (dronabinol, nabilone) have specific approvals [1].
• Safety concerns consistently highlighted include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination/labeling inaccuracy, and THC-vape lung injury [1].

CBD: The Most Evidence-Developed Non-Intoxicating Cannabinoid

Evidence profile: Strongest human evidence in this formula set, especially as purified product [1]-[6].

Best supported: Purified CBD has the most credible human evidence in seizure disorders, clearly acknowledged by institutional and peer-reviewed literature [1][2].

Anxiety research: A 2024 systematic review/meta-analysis covering 316 participants across eight articles reported statistically significant anxiolytic signal, but authors stress the clinical sample remains limited and more trials are needed [3].

Pain research: A 2024 systematic review of CBD monotherapy studies concluded the pain literature is promising but heterogeneous, with trial quality limiting broad analgesic claims [4].

Sleep research: A 2023 insomnia review found literature remains methodologically weak, with many studies relying on nonvalidated subjective measures [5].

Safety concerns: A 2023 systematic review found real signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH flags diarrhea, sleepiness, appetite changes, mood effects, liver abnormalities, and drug-drug interactions [1].

Bottom line for Oklahomans: CBD is the most evidence-developed nonintoxicating cannabinoid, but strong evidence is concentrated in specific indications rather than broad wellness claims [1]-[6].

CBG: The “Mother Cannabinoid” with Emerging Research

Evidence profile: Mostly review-level and preclinical; human evidence remains sparse [7][8].

Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids with pharmacologically distinct properties spanning cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A signaling — mechanistically interesting but not yet clinically established [7].

Research areas: Reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are pharmacology-led hypotheses rather than mature human conclusions [7][8].

Caution: The 2021 pharmacology review explicitly notes CBG is being sold commercially while evidence base remains thin, meaning claims frequently outrun science [7].

Bottom line for Oklahomans: CBG is a serious research topic but should be described as promising with limited clinical validation rather than proven therapeutic [7][8].

Delta-8 THC: Not Just “Diet Weed”

Evidence profile: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11].

Comparative pharmacology: A 2022 review concluded delta-8 and delta-9 THC have broadly similar pharmacokinetic/pharmacodynamic behavior. Delta-8 is a partial CB1 agonist with cannabimimetic activity, but appears less potent, likely due to weaker CB1 affinity [9].

Public health literature: A 2023 scoping review found the evidence base dominated by animal studies, product chemistry, use reports, and public health concerns rather than strong human trials. Reports of adverse consequences and regulatory/product-quality concerns were noted [10].

Manufacturing context: Commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which raises product-byproduct and lab-testing questions [11].

Bottom line for Oklahomans: Delta-8 THC is a psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many realize [9]-[11]. Do not assume it’s “safe because it’s hemp-derived.”

THCa: The Legal Cannabis Game-Changer

Evidence profile: Important chemically/formulation-wise, but low on direct human therapeutic evidence [12].

What it is: THCa is the acidic precursor to THC and may represent a large share of THC-related content in raw plant material. It decarboxylates to THC during heating and can change during storage/processing [12].

Psychoactivity: THCa itself does not produce psychoactive effects associated with THC, but only if it stays in acidic form and is not substantially decarboxylated [12].

Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].

Bottom line for Oklahomans: THCa is best understood as a highly relevant precursor whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa must account for possible conversion into THC [12].

Delta-9 THC: Strongest Evidence but Clearest Risks

Evidence profile: Strongest human evidence of psychoactive cannabinoids listed, but also clearest adverse-effect burden [1][13]-[15].

Institutionally best supported: NCCIH identifies THC-containing medicines as relevant to chemotherapy nausea/vomiting, HIV/AIDS appetite/weight loss, and some MS/pain outcomes, while stressing many other uses remain uncertain [1].

Pain evidence: A 2022 systematic review found high-THC products or comparable THC:CBD ratios may provide short-term pain benefit but increase dizziness, sedation, nausea, and treatment discontinuation [13].

Pharmacokinetics: Inhaled THC: effects within seconds-minutes, peak 15-30 minutes, taper over hours. Oral THC: later onset, later peak, longer duration — important for both benefit and overconsumption risk [14].

Mental health risk: A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, with concerning signals for anxiety and depression in nontherapeutic settings [15].

Broader safety: Anxiety/panic at high doses, tachycardia, blood pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, vape-related lung injury concerns [1][14][15].

Bottom line for Oklahomans: Delta-9 THC has legitimate therapeutic relevance in some settings, but carries the clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15].

CBN: The “Sleep Cannabinoid” with Weak Evidence

Evidence profile: Weak human evidence; marketing has moved ahead of data [12][16][17].

Marketing vs. reality: CBN is widely marketed for sleep, but clinical support is far thinner than the market suggests [16][17].

Best direct review: A 2021 narrative review screened 99 human-study abstracts, reviewed 8 full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN [16].

2024 update: A 2024 review concluded overall cannabinoid sleep research still doesn’t match real-world use scale, and need for better-designed, adequately powered trials remains substantial [17].

Bottom line for Oklahomans: CBN is one of the clearest examples where cultural reputation is stronger than current clinical evidence base [16][17]. Our formula includes it at 750 mg because the mechanistic rationale is plausible, but we don’t overstate the evidence.

CBC: Emerging but Preclinical

Evidence profile: Emerging, intriguing, overwhelmingly preclinical or review-based [18][19].

Pharmacology: A 2024 review argues CBC has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, highlighting antinociceptive, antibacterial, and anti-seizure areas as interesting research targets [18].

Older literature: Review literature summarizing CBC in animal/in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, possible neurobiological or antiproliferative relevance — not yet strong patient-facing evidence [19].

Safety caveat: The 2024 CBC review explicitly notes over-the-counter CBC products are being sold despite little evidence establishing clinical efficacy or safety [18].

Bottom line for Oklahomans: CBC belongs in the scientifically credible minor cannabinoid category that deserves more research, not already-validated clinical actives [18][19].

Terpenes: The Aromatic Dimension

Terpene claims need even stricter interpretation than cannabinoid claims. Most literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models. Robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene (Citrus-Bright)

Evidence profile: Largely review and preclinical, with useful safety literature [20]-[22].

Potential activity: A 2021 review describes antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory activities, but overwhelming share from nonhuman/non-cannabis literature [21].

Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing [22].

Bottom line: Biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22].

Myrcene

Evidence profile: Mostly preclinical, very limited human evidence [20][23].

Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties and possible mechanisms, but explicitly states human studies are lacking [23].

Interpretation caution: Myrcene is often invoked as a proven sedative that explains “couch-lock.” That claim is stronger than current human evidence supports [20][23].

Bottom line: Plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23].

Caryophyllene (Pepper/Spice)

Evidence profile: Among most mechanistically interesting because of direct cannabinoid-system relevance, but still mostly preclinical [24].

Why it stands out: A 2021 review describes beta-caryophyllene as a selective CB2 receptor agonist — unusual and especially relevant when discussing cannabis terpenes pharmacologically rather than purely aromatically [24].

Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions discussed, but human clinical confirmation remains limited [24].

Bottom line: Arguably the strongest candidate terpene with cannabinoid-system significance, but still should not be described as clinically proven for commonly attributed outcomes [24].

Pinene (Forest-Fresh)

Evidence profile: Promising preclinical literature, weak human confirmation [20][25].

Brain-health framing: A 2021 review on pinene and linalool found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized lack of well-designed clinical trials [25].

Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC cognitive effects remain interesting hypotheses rather than settled facts [20][25].

Bottom line: Deserves scientific attention, but strong cognition claims should be presented as exploratory [25].

Linalool (Floral, Lavender)

Evidence profile: Substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].

Research summary: Linalool is repeatedly discussed for stress, mood, and brain-health pharmacology. The 2021 brain-health review found enough preclinical signal to justify continued investigation while emphasizing lack of robust human trials [25].

Additional literature: Separate reviews discuss possible antidepressant mechanisms and neuropharmacologic relevance, but this remains translational rather than definitive clinical story [26].

Safety note: Oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22].

Bottom line: Scientifically credible bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene (Earthy, Woody)

Evidence profile: Translationally interesting, still early [20][27].

Scoping-review findings: A 2024 scoping review analyzed 340 articles, finding broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].

Interpretation caution: Findings are valuable for hypothesis generation but don’t yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].

Bottom line: One of the more interesting terpene research targets, but remains far from clinically settled [27].

Terpinolene (Piney, Fruity, Sparkling)

Evidence profile: One of the least clinically characterized terpenes in this file [20][28].

Systematic-review findings: A 2021 review screened 2,449 records, included 57 studies, and concluded terpinolene has range of reported biological effects but evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials [28].

Bottom line: Biologically interesting, but especially underdeveloped clinically among listed terpenes [20][28].

Research Limits and Interpretation: What Oklahomans Must Know

Five critical interpretation rules:

1. Evidence is highly uneven. CBD and delta-9 THC can support detailed human-facing statements; the rest require more caution.

2. Extract/molecule/synthetic/terpene data aren’t interchangeable. One common error is letting evidence from one category stand in for another.

3. Minor cannabinoids are commercially interesting BECAUSE they’re underexplored. This means claims often become inflated.

4. Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect real-world outcomes [1][10][11][14].

5. THCa chemistry changes with storage/heating. Storage and heating can change exposure profile by converting acidic cannabinoids to neutral cannabinoids like THC [12].

Common Overstatements to Avoid (And What to Say Instead)

Overstatement	More Accurate Version
“CBN is a clinically proven sleep cannabinoid”	“Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified” [16][17]
“Myrcene is a proven human sedative that explains couch-lock”	“Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited” [20][23]
“Terpenes have proven entourage effects in patients”	“Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific” [20][29]
“THCa is always non-psychoactive”	“THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure” [12]
“Delta-8 THC is safe because it’s hemp-derived”	“Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns” [9]-[11]

Practical Takeaways for Our Formulas

1. CBD and delta-9 THC are most evidence-developed in this formula set.
2. Delta-8 THC is not trivial or purely mild; it’s a psychoactive cannabinoid with less robust safety/efficacy characterization than delta-9 THC.
3. THCa changes meaningfully with processing; interpret differently for raw vs. heated formats.
4. CBG, CBN, and CBC are scientifically credible but clinically immature compared to CBD and THC.
5. Terpene claims should be careful; current evidence supports cautious phrasing rather than firm therapeutic promises.

References [1]-[29]

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know

2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.

3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.

4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.

5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.

6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.

7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.

8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.

9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.

10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.

11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.

12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.

13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.

14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.

15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.

16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.

17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.

18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.

19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.

20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.

21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.

22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.

23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.

24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.

25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.

26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.

27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.

28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.

29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

A Final Word to Oklahomans

We at OilWell Cannabis aren’t here to sell you a miracle cure. We’re here to give you the most thoroughly researched, transparently manufactured, legally accessible multi-cannabinoid RSO available in Oklahoma today. Whether you’re in Oklahoma City dealing with chronic pain, in Tulsa managing cancer treatment side effects, in Lawton fighting PTSD, or in any of Oklahoma’s 77 counties seeking alternatives to pharmaceuticals that have failed you — we see you.

Our promise is simple: honest education, professional manufacturing, legal access, and published formulas you can replicate if you need to. We bring Houston’s medical-center precision to your Oklahoma home. We bring a decade of formulation driven by love for a dog who got up and walked again. We bring media-verified credibility and a personal history of overcoming the same struggles you face.

Order today: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/

Questions? Call (832) 416-2816 or email [email protected]

Follow us: @oilwellcbd on Instagram

Thank you, Oklahoma, for trusting us with your health. We’ll never stop working to earn that trust.

Age requirement: 21+ for all RSO products. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before use. Keep out of reach of children. Do not operate vehicles or machinery while using psychoactive cannabinoids. Buyer assumes responsibility for compliance with local laws. Void where prohibited.